{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T13:50:32Z","timestamp":1768830632431,"version":"3.49.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:00:00Z","timestamp":1609545600000},"content-version":"vor","delay-in-days":367,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.jjcc.2019.09.002","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:02:07Z","timestamp":1571097727000},"page":"27-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Clinical findings of gadolinium-enhanced cardiac magnetic resonance in Fabry patients"],"prefix":"10.1016","volume":"75","author":[{"given":"Ayumi","family":"Nojiri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuko","family":"Anan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Sakuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahisa","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Ida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toya","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikatsu","family":"Eto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihiro","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Hongo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2019.09.002_bib0005","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","article-title":"Fabry disease: guidelines for the evaluation and management of multi-organ system involvement","volume":"8","author":"Eng","year":"2006","journal-title":"Genet Med"},{"key":"10.1016\/j.jjcc.2019.09.002_bib0010","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"12","author":"Ortiz","year":"2018","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.jjcc.2019.09.002_bib0015","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.2174\/13816128113199990352","article-title":"Anderson-Fabry disease: a multiorgan disease","volume":"19","author":"Tuttolomondo","year":"2013","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jjcc.2019.09.002_bib0020","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1136\/heartjnl-2014-306278","article-title":"Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease","volume":"101","author":"Talbot","year":"2015","journal-title":"Heart"},{"key":"10.1016\/j.jjcc.2019.09.002_bib0025","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.beem.2014.10.003","article-title":"Fabry disease and the heart","volume":"29","author":"Seydelmann","year":"2015","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.jjcc.2019.09.002_bib0030","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.02.019","article-title":"Characteristics of cerebral microbleeds in patients with Fabry disease","volume":"25","author":"Kono","year":"2016","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.jjcc.2019.09.002_bib0035","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10741-014-9452-9","article-title":"Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment","volume":"20","author":"Putko","year":"2015","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jjcc.2019.09.002_bib0040","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s12551-018-0432-5","article-title":"Anderson-Fabry disease in heart failure","volume":"10","author":"Akhtar","year":"2018","journal-title":"Biophys Rev"},{"key":"10.1016\/j.jjcc.2019.09.002_bib0045","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ymgme.2018.04.008","article-title":"The beneficial effects of long-term enzyme replacement therapy on cardiac involvement in Japanese Fabry patients","volume":"124","author":"Hongo","year":"2018","journal-title":"Mol Genet Metab"},{"issue":"Suppl. 3","key":"10.1016\/j.jjcc.2019.09.002_bib0050","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10545-007-0740-6","article-title":"Clinical manifestations and natural history of Japanese heterozygous females with Fabry disease","volume":"31","author":"Kobayashi","year":"2008","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.jjcc.2019.09.002_bib0055","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10741-007-9060-z","article-title":"Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies","volume":"13","author":"Wright","year":"2008","journal-title":"Heart Fail Rev"},{"issue":"Suppl. A","key":"10.1016\/j.jjcc.2019.09.002_bib0060","doi-asserted-by":"crossref","first-page":"A13","DOI":"10.1253\/circj.CJ-08-0481","article-title":"Molecular mechanisms underlying the transition of cardiac hypertrophy to heart failure","volume":"72","author":"Oka","year":"2008","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2019.09.002_bib0065","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.jcmg.2017.08.005","article-title":"Role of cardiac magnetic resonance in the diagnosis and prognosis of nonischemic cardiomyopathy","volume":"10","author":"Patel","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jjcc.2019.09.002_bib0070","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ijcard.2017.10.094","article-title":"Impact of late gadolinium enhancement on mortality, sudden death and major adverse cardiovascular events in ischemic and nonischemic cardiomyopathy: a systematic review and meta-analysis","volume":"254","author":"Ganesan","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jjcc.2019.09.002_bib0075","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jjcc.2011.07.007","article-title":"Scoring of late gadolinium enhancement in cardiac magnetic resonance imaging can predict cardiac events in patients with hypertrophic cardiomyopathy","volume":"58","author":"Nojiri","year":"2011","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2019.09.002_bib0080","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0002-9149(76)90491-4","article-title":"Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy","volume":"37","author":"Teichholz","year":"1976","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jjcc.2019.09.002_bib0085","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.echo.2015.05.002","article-title":"Recommendations on the use of echocardiography in adult hypertension: a report from the european association of cardiovascular imaging (EACVI) and the american society of echocardiography (ASE)","volume":"28","author":"Marwick","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jjcc.2019.09.002_bib0090","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/eurheartj\/ehi258","article-title":"Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies","volume":"26","author":"Mahrholdt","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2019.09.002_bib0095","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jcmg.2011.01.020","article-title":"Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment","volume":"4","author":"Niemann","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jjcc.2019.09.002_bib0100","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.jacc.2016.09.943","article-title":"Later onset Fabry disease, cardiac damage progress in silence: experience with a highly prevalent mutation","volume":"68","author":"Hsu","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2019.09.002_bib0105","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ymgme.2018.11.005","article-title":"Early detection of organ involvement in Fabry disease by biomarker assessment in conjunction with LGE cardiac MRI: results from the SOPHIA study","volume":"126","author":"Weidemann","year":"2019","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.jjcc.2019.09.002_bib0110","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12968-015-0111-7","article-title":"Normal values for cardiovascular magnetic resonance in adults and children","volume":"17","author":"Kawel-Boehm","year":"2015","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.jjcc.2019.09.002_bib0115","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2019.09.002_bib0120","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jacc.2010.05.010","article-title":"Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy","volume":"56","author":"O\u2019Hanlon","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2019.09.002_bib0125","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.jacc.2010.05.007","article-title":"Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy","volume":"56","author":"Bruder","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2019.09.002_bib0130","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.amjcard.2014.06.019","article-title":"Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry disease","volume":"114","author":"Kr\u00e4mer","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jjcc.2019.09.002_bib0135","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1136\/heartjnl-2014-306278","article-title":"Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease","volume":"101","author":"Talbot","year":"2015","journal-title":"Heart"},{"key":"10.1016\/j.jjcc.2019.09.002_bib0140","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s10741-015-9500-0","article-title":"Fabry\u2019s disease: an example of cardiorenal syndrome type 5","volume":"20","author":"Sharma","year":"2015","journal-title":"Heart Fail Rev"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508719302928?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508719302928?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:01:59Z","timestamp":1760274119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508719302928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0914508719302928"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2019.09.002","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical findings of gadolinium-enhanced cardiac magnetic resonance in Fabry patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2019.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}